These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 35202165)

  • 1. Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine.
    van Heuvel Y; Schatz S; Rosengarten JF; Stitz J
    Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).
    Fitzgerald DW; Janes H; Robertson M; Coombs R; Frank I; Gilbert P; Loufty M; Mehrotra D; Duerr A;
    J Infect Dis; 2011 Mar; 203(6):765-72. PubMed ID: 21343146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques.
    McBrien JB; Wong AKH; White E; Carnathan DG; Lee JH; Safrit JT; Vanderford TH; Paiardini M; Chahroudi A; Silvestri G
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of feline immunodeficiency virus (FIV).
    Mohammadi H; Bienzle D
    Viruses; 2012 May; 4(5):708-24. PubMed ID: 22754645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action.
    Tazi J; Bakkour N; Marchand V; Ayadi L; Aboufirassi A; Branlant C
    FEBS J; 2010 Feb; 277(4):867-76. PubMed ID: 20082634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The levels of DNGR-1 and its ligand-bearing cells were altered after human and simian immunodeficiency virus infection.
    Yao WR; Li D; Yu L; Wang FJ; Xing H; Yang GB
    Immunol Res; 2017 Aug; 65(4):869-879. PubMed ID: 28478499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
    Iribarren JA; Labarga P; Rubio R; Berenguer J; Miró JM; Antela A; González J; Moreno S; Arrizabalaga J; Chamorro L; Clotet B; Gatell JM; López-Aldeguer J; Martínez E; Polo R; Tuset M; Viciana P; Santamaría JM; Kindelán JM; Ribera E; Segura F; ;
    Enferm Infecc Microbiol Clin; 2004 Dec; 22(10):564-642. PubMed ID: 15596051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy.
    Moretti S; Cafaro A; Tripiciano A; Picconi O; Buttò S; Ensoli F; Sgadari C; Monini P; Ensoli B
    Expert Rev Vaccines; 2020 Jan; 19(1):71-84. PubMed ID: 31957513
    [No Abstract]   [Full Text] [Related]  

  • 10. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
    Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
    J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir.
    Avalos CR; Abreu CM; Queen SE; Li M; Price S; Shirk EN; Engle EL; Forsyth E; Bullock BT; Mac Gabhann F; Wietgrefe SW; Haase AT; Zink MC; Mankowski JL; Clements JE; Gama L
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of replication-competent viral vectors for HIV vaccine delivery.
    Parks CL; Picker LJ; King CR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):402-11. PubMed ID: 23925000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines.
    Kang CY; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):47. PubMed ID: 28893272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
    Schooley RT; Spritzler J; Wang H; Lederman MM; Havlir D; Kuritzkes DR; Pollard R; Battaglia C; Robertson M; Mehrotra D; Casimiro D; Cox K; Schock B;
    J Infect Dis; 2010 Sep; 202(5):705-16. PubMed ID: 20662716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.
    Yamamoto H; Kawada M; Tsukamoto T; Takeda A; Igarashi H; Miyazawa M; Naruse T; Yasunami M; Kimura A; Matano T
    J Gen Virol; 2007 Feb; 88(Pt 2):652-659. PubMed ID: 17251584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
    Loret EP; Darque A; Jouve E; Loret EA; Nicolino-Brunet C; Morange S; Castanier E; Casanova J; Caloustian C; Bornet C; Coussirou J; Boussetta J; Couallier V; Blin O; Dussol B; Ravaux I
    Retrovirology; 2016 Apr; 13():21. PubMed ID: 27036656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
    J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Will It Take to Cure HIV?
    Ananworanich J
    Top Antivir Med; 2015; 23(2):80-4. PubMed ID: 26200707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.